As per the report titled ‘Peptide Based Cancer Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Type; By Cancer Type; By Mode of Mechanism, By Distribution Channel, By Regions; Segment Forecast, 2020 -2027’, available with Market Study Report, global peptide based cancer therapeutics market is anticipated to record an appreciable growth rate during 2020-2027, subsequently accounting for 17.18 billion by the year 2027.
 

According to the findings of the report, global peptide based cancer therapeutics market is majorly driven by increasing cancer screening programs in emerging countries and rising burden of cancer worldwide. In fact, an analysis by the United States’ National Cancer Center states that 1,010,200 cancer cases were recorded in 2016, of which 434,100 cases were of women and 576,100 of male. The mortality rate in 2016 peaked with cancer claiming the lives of 374,000 individuals.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2963822/
 

For the uninitiated, peptides are natural or artificial biological compounds of amino acid monomers. Peptides are witnessing a widespread adoption for treating several ailments, including cancer due to their efficacy in targeting solid tumor cells in the body. Moreover, peptide based cancer therapeutics offer easy administration and have better results with less side effects in comparison to conventional cancer treatments, thereby rendering a positive impact on global peptide based cancer therapeutics industry.
 

Global peptide based cancer therapeutics market size spans across North America (US, Canada), Europe (UK, France, Italy, Germany, Spain, Netherlands, Austria), Asia Pacific (India, China, Japan, Malaysia, Indonesia, Japan, South Korea), Latin America (Mexico, Argentina, Brazil), and Middle East & Africa (UAE, Saudi Arabia, Israel, South Africa).
 

Leading players influencing the global peptide based cancer therapeutics market outlook are Valeant Pharmaceuticals, Inc., AbbVie, Inc., Johnson & Johnson, Amgen, Inc., Takeda Pharmaceutical Co., Ltd., Pfizer, Inc., Teva Pharmaceuticals, Allergan plc, Abbott Laboratories, and AstraZeneca plc. These industry giants are entering strategic agreements and undertaking collaborations & partnerships to improve their market stance. For instance, AstraZeneca, in June 2017, together with National Cancer Institute signed a cooperative R&D agreement with eleven Biopharmaceutical companies to develop Vicinium and AstraZeneca's Imfinzi, an immune checkpoint inhibitor for treating non-muscle invasive bladder cancer.